Connect to other sites within the UBM Medica Network
FDA Approves Elotuzumab, Second Monoclonal Antibody Treatment for Multiple Myeloma
On November 30, 2015, the US Food and Drug Administration (FDA) approved elotuzumab (Empliciti, Bristol-Myers Squibb) as a second-line treatment for multiple myeloma, in combination with two other agents.
Chemotherapy Plus Lenalidomide Inferior to Standard for Myeloma
Chemotherapy plus lenalidomide was shown to be inferior to high-dose melphalan and ASCT in transplant-eligible patients with newly diagnosed multiple myeloma.
Elotuzumab Effective, Safe for Relapsed, Refractory Myeloma
Adding elotuzumab to lenalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma appears to result in better efficacy and safety.
FDA Approves Ixazomib (Ninlaro) for Multiple Myeloma
The FDA approved the proteasome inhibitor ixazomib, in combination with lenalidomide and dexamethasone, to be used as a second-line treatment in multiple myeloma.
Daratumumab Granted FDA Approval for Treatment-Resistant Multiple Myeloma
On November 16, 2015, the US Food and Drug Administration (FDA) approved daratumumab (Darzalex) to treat patients with multiple myeloma who have received at least three prior treatments.
Myeloma-Related Kidney Failure Declined in Recent Years
The risk for end-stage renal disease that required renal replacement therapy due to multiple myeloma appears to have declined significantly between 2001 and 2010.
Carfilzomib/Pomalidomide Active in Relapsed, Refractory Myeloma
A novel regimen of carfilzomib, pomalidomide, and dexamethasone was highly active in a group of heavily pretreated patients with relapsed or refractory multiple myeloma.
By clicking Accept, you agree to become a member of the UBM Medica Community.